bioAffinity Technologies Unveils New Research Supporting CyPath Lung Test at CHEST 2025

Reuters10-20
bioAffinity Technologies Unveils New Research Supporting CyPath Lung Test at CHEST 2025

bioAffinity Technologies Inc. has announced that it will present new research supporting the methods used for collecting and transporting patient samples for its noninvasive CyPath® Lung test at CHEST 2025, the annual meeting of the American College of Chest Physicians. The study, titled "The Effect of Sputum Storage and Shipping Temperature on Flow Cytometric Outcomes of Sputum-Based Diagnostic Tests," will be presented by Dr. Rossella Titone on October 22, 2025. The research highlights protocols for handling clinical samples collected at home and returned to the laboratory, with physicians typically receiving results within two days. The company has previously reported that CyPath® Lung has detected lung cancer at early, potentially curative stages.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. bioAffinity Technologies Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20251020425174) on October 20, 2025, and is solely responsible for the information contained therein.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment